Dr. O'Regan Discusses Updates in HER2-Positive Breast Cancer

Ruth M. ORegan, MD
Published: Thursday, Aug 14, 2014

Ruth M. O’Regan, MD, director, Translational Breast Cancer Research, professor, hematology and oncology, medical oncology, Winship Cancer Institute, Emory University, discusses updates in the field of adjuvant therapy for HER2-positive breast cancer.

At the 13th Annual International Congress on the Future of Breast Cancer, O’Regan discussed novel insights into adjuvant therapy for HER2-positive breast cancer. O’Regan says she reviewed how far we’ve come by using trastuzumab-based chemotherapy. O’Regan also noted that it appears that the addition of more novel therapies will not improve outcomes in this population of patients.

Physicians need to discuss if their patients can receive less trastuzumab if tumors are small and if molecular testing to determine which patients would benefit from trastuzumab is an option, O’Regan says. The idea of giving less or no chemotherapy is also being discussed for patients in this space. O’Regan says more research is needed.
 
Ruth M. O’Regan, MD, director, Translational Breast Cancer Research, professor, hematology and oncology, medical oncology, Winship Cancer Institute, Emory University, discusses updates in the field of adjuvant therapy for HER2-positive breast cancer.

At the 13th Annual International Congress on the Future of Breast Cancer, O’Regan discussed novel insights into adjuvant therapy for HER2-positive breast cancer. O’Regan says she reviewed how far we’ve come by using trastuzumab-based chemotherapy. O’Regan also noted that it appears that the addition of more novel therapies will not improve outcomes in this population of patients.

Physicians need to discuss if their patients can receive less trastuzumab if tumors are small and if molecular testing to determine which patients would benefit from trastuzumab is an option, O’Regan says. The idea of giving less or no chemotherapy is also being discussed for patients in this space. O’Regan says more research is needed.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x